Bronchiectasis and other chronic lung diseases in adolescents living with HIV by Attia, EF et al.
1		
Bronchiectasis	and	other	chronic	lung	diseases	in	adolescents	living	with	HIV			Engi	F	Attia1,	Robert	F	Miller	2,3,	Rashida	A	Ferrand3,4		1	Pulmonary	and	Critical	Care	Medicine,	University	of	Washington,	Seattle,	WA,	USA	2	Research	Department	of	Infection	and	Population	Health,	University	College	London,	London,	UK	3	Clinical	Research	Department,	London	School	of	Hygiene	&	Tropical	Medicine,	London,	UK	4	Biomedical	Research	&	Training	Institute,	Harare,	Zimbabwe			Corresponding	Author:		Dr	Rashida	Ferrand,		Clinical	Research	Department,		London	School	of	Hygiene	&	Tropical	Medicine,		Keppel	Street,		London	WC1E	7HT,	UK		Tel:	+44	207	927	2577	Email:	rashida.ferrand@lshtm.ac.uk				
Keywords:	Adolescent,	HIV,	bronchiectasis,	lymphocytic	interstitial	pneumonitis,	obliterative	bronchiolitis,	chronic	lung	disease				 	
2		
Abstract		
Purpose	of	review:	The	 incidence	of	pulmonary	 infections	has	declined	dramatically	with	 improved	access	to	antiretroviral	 therapy	(ART)	and	 co-trimoxazole	 prophylaxis,	 but	 chronic	 lung	 disease	 (CLD)	 is	 an	 increasingly	 recognized	 but	 poorly	 understood	 complication	 in	adolescents	with	perinatally-acquired	HIV.		
Recent	 findings:	 There	 is	 a	high	prevalence	of	 chronic	 respiratory	 symptoms,	 abnormal	 spirometry	 and	 chest	 radiographic	 abnormalities	among	HIV-infected	adolescents	in	sub-Saharan	Africa,	where	90%	of	the	world’s	HIV-infected	children	live.	The	incidence	of	lymphocytic	interstitial	pneumonitis,	the	most	common	cause	of	CLD	in	the	pre-ART	era,	has	declined	with	increased	ART	access.	Small	airways	disease,	particularly	constrictive	obliterative	bronchiolitis	and	bronchiectasis	are	emerging	as	leading	causes	of	CLD	among	HIV-infected	adolescents	in	low-	and	middle-income	countries.	Asthma	may	be	more	common	in	high-income	settings.	Likely	risk	factors	for	CLD	include	recurrent	pulmonary	infections,	air	pollution,	HIV-related	immune	dysfunction	and	untreated	HIV	infection,	particularly	during	critical	stages	of	lung	development.	
Summary:	 Globally,	 the	 importance	 of	HIV-associated	 CLD	 as	 a	 cause	 of	morbidity	 and	mortality	 is	 increasing,	 especially	 as	 survival	 has	improved	dramatically	with	ART	and	growing	numbers	of	children	living	with	HIV	enter	adolescence.	Further	research	is	urgently	needed	to	elucidate	the	natural	history	and	pathogenesis	of	CLD,	and	to	determine	optimal	screening,	diagnostic	and	treatment	strategies.		 	
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Introduction	Of	the	estimated	3.4	million	children	living	with	HIV	globally,	90%	live	in	sub-Saharan	Africa	[1].	Although	the	number	of	children	born	with	HIV	 is	 declining	 due	 to	 scale-up	 of	 prevention	 of	mother-to-child	 transmission	 (PMTCT)	 programmes,	 growing	 numbers	 of	HIV-infected	children	are	 surviving	 to	adolescence	due	 to	 the	widespread	roll-out	of	antiretroviral	 therapy	 (ART)	 [2].	 In	addition,	 approximately	one-third	of	HIV-infected	infants	survive	to	adolescence	in	the	absence	of	ART,	and	children	infected	a	decade	ago	when	PMTCT	programmes	and	early	infant	diagnosis	were	not	available,	are	now	presenting	to	health	services	in	large	numbers	for	the	first	time	in	older	childhood	and	adolescence	[3].	Consequently,	the	burden	of	paediatric	HIV	is	shifting	toward	adolescents	[2].			While	the	incidence	of	acute	pulmonary	infections	in	HIV	is	declining	due	to	the	use	of	co-trimoxazole	prophylaxis	and	ART	[4-6,7**],	chronic	lung	disease	 (CLD)	 is	 emerging	as	an	 important,	but	 incompletely	understood,	 complication	among	older	 children	and	adolescents	 living	with	HIV	[8*].	In	particular,	adolescents	with	delayed	diagnosis	of	perinatally-acquired	HIV	have	a	disproportionately	high	burden	of	chronic	respiratory	disease	[8*,9*,10*,11*].	We	review	the	spectrum	of	and	risk	factors	for	HIV-associated	CLD	among	adolescents	living	with	HIV,	as	well	as	considerations	in	diagnosis	and	management.			
Spectrum	of	chronic	lung	disease	Recent	studies	from	sub-Saharan	Africa	highlight	a	substantial	burden	of	chronic	respiratory	symptoms	and	poor	lung	function	among	HIV-infected	adolescents.	Over	half	of	older	children	and	adolescents	reported	at	least	one	chronic	respiratory	symptom	in	recent	studies	from	Zimbabwe,	Malawi	and	Kenya	[8*,10*,11*,12*,13*,14*].	Chronic	cough	and	sputum	production	were	reported	by	21-60%	and	breathlessness	by	12-18%,	but	wheezing	was	uncommon	[8*,10*,11*,12*,13*,14*,15*].	The	prevalence	of	tachypnoea	is	difficult	to	quantify	as	definitions	vary	between	studies,	but	elevated	respiratory	rates	are	common	[8*,9*,10*,11*,	15*].	Hypoxia	after	sub-maximal	exercise	was	a	striking	finding	 among	 12-38%	 [10*,11*,12*,13*,15*,16*].	 One-third	 of	 adolescents	 had	 abnormal	 spirometry:	 forced	 expiratory	 volume	 in	 one	second	(FEV1)	and	forced	vital	capacity	(FVC)	were	lower	among	those	with	HIV,	compared	to	age-,	sex-,	race-	and	height-adjusted	predicted	values,	 and	 compared	 to	 HIV-uninfected	 controls	 [8*,15*,17].	 While	 some	 studies	 documented	 a	 substantial	 prevalence	 of	 airflow	
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obstruction	 [10*,11*,12*],	 others	 reported	 a	 prominence	 of	 a	 restricted	 pattern	 [11*,13*,14*];	 there	 was	 little	 reversibility	 with	bronchodilators.	One	study	additionally	measured	lung	volumes,	compliance	and	transfer	factor	for	carbon	monoxide,	finding	that	each	was	lower	among	HIV-infected	compared	to	uninfected	participants	[18**].	A	recent	study	from	the	USA	also	showed	a	high	prevalence	of	poorly	reversible	airflow	obstruction	[19*].	Taken	together,	these	studies	suggest	that	CLD	may	be	more	common	among	HIV-infected	adolescents	than	previously	appreciated	(Table	1).		The	term	CLD	comprises	a	spectrum	of	lung	diseases	whose	prevalence	varies	between	LMICs	and	high-income	countries.	The	pathogenesis	is	multifactorial,	but	HIV-related	immune	dysfunction	is	likely	important.				
	
Bronchiectasis	Bronchiectasis	 is	 a	 well-recognized	 and	 irreversible	 cause	 of	 CLD	 among	 HIV-infected	 children	 and	 adolescents	 [20].	 The	 bronchial	architecture	 is	 distorted	 with	 bronchial	 diameter	 enlargement	 relative	 to	 the	 adjacent	 pulmonary	 artery,	 which	 appears	 as	 a	 “ring”	 or	“tramline”	pattern	on	chest	radiography	[21*,22*].	A	study	from	the	USA	in	the	pre-ART	era	reported	that	6%	of	749	HIV-infected	children	without	pre-existing	lung	disease	developed	radiographically	or	histologically	determined	bronchiectasis	during	an	average	of	six	years	of	follow-up	[23].	In	contrast,	in	two	recent	studies	conducted	in	Zimbabwe	and	Malawi	among	older	children	and	adolescents	with	perinatally-acquired	HIV,	one-half	had	chest	radiographic	features	consistent	with	bronchiectasis	[8*,11*].	Two-thirds	of	children	in	the	African	studies	were	on	ART	for	at	least	a	median	duration	of	20	months	and	had	median	CD4	>350	cells/µL.	The	lower	prevalence	of	bronchiectasis	in	the	USA	study	despite	unavailability	of	ART	was	probably	due	to	earlier	engagement	with	healthcare	services,	prompt	treatment	of	infections	and	greater	attention	to	maintaining	adequate	nutrition.			Multiple	 insults	 can	 result	 in	 bronchiectasis,	 including	 recurrent	 pulmonary	 infections,	 chronic	 aspiration,	 and	 congenital	 or	 acquired	immunodeficiency	 syndromes	 [17,20,21*,22*,23,24].	 HIV	 is	 associated	 with	 an	 increased	 risk	 of	 tuberculosis,	 and	 recurrent	 viral	 and	bacterial	pulmonary	infections	[7**,17,23,24,25*,26].	However,	some	data	suggest	that	HIV	predisposes	to	bronchiectasis	independently	of	infection,	 likely	 due	 to	 HIV-mediated	 defects	 in	 innate	 immunity	 and	 accompanying	 airway	 neutrophilic	 inflammation	 [17,21*,22*,27].	
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Bronchiectasis	 in	 adolescents	 can	 also	 occur	 as	 a	 late	 complication	 of	 lymphocytic	 interstitial	 pneumonitis	 (LIP)	 [24].	 Bronchiectasis	accounts	for	a	substantial	proportion	of	chronic	respiratory	symptoms,	reduced	quality	of	life	and	risk	of	premature	death	[22*].	
	
Constrictive	obliterative	bronchiolitis	In	2012,	Ferrand	and	colleagues	first	reported	a	high	prevalence	of	chronic	respiratory	symptoms	among	perinatally	HIV-infected	children	diagnosed	 in	 adolescence,	 nearly	 three-quarters	 of	 whom	 were	 taking	 ART	 [8*].	 This	 was	 the	 first	 study	 to	 perform	 high-resolution	computed	 tomography	 (HRCT)	 in	 this	 context.	 Among	 the	 56	 adolescents	with	 chronic	 respiratory	 symptoms,	 the	most	 common	HRCT	finding	was	 a	mosaic	 pattern	of	 decreased	 attenuation	 in	55%	 (Figure	1).	Decreased	 attenuation	was	 associated	with	 reduced	FEV1	 and	chronic	cough	[16*].	Together	with	hypoxia	and	irreversible	airflow	obstruction,	these	findings	are	consistent	with	constrictive	obliterative	bronchiolitis	(cOB).	This	was	the	first	study	to	demonstrate	cOB	as	a	major	cause	of	CLD.	To	our	knowledge,	there	are	no	reports	of	HIV-associated	cOB	among	adolescents	 in	high-income	settings,	although	 the	 findings	by	Shearer	and	colleagues	could	partly	be	explained	by	small	airways	disease	[19*].	Due	to	the	cross-sectional	nature	of	these	data,	however,	it	is	not	possible	to	determine	whether	findings	reflect	abnormalities	persisting	from	insults	during	childhood	or	recent-onset	disease	[28*].			The	pathogenesis	 and	natural	 history	of	 cOB	among	HIV-infected	 adolescents	 is	 not	well	 understood.	This	 rare,	 usually	progressive,	 and	fibrotic	and	inflammatory	condition	involves	the	small	airways	involved	in	gas	exchange,	namely	the	terminal	and	respiratory	bronchioles,	but	 spares	 the	 lung	parenchyma	 [29].	These	bronchiolar	 lesions	 are	patchy	and	may	be	missed	on	 transbronchial	 biopsy.	Clinically,	 cOB	presents	 with	 progressive	 dyspnea	 and	 cough	 over	 weeks	 to	months,	 and	 hypoxia	may	 be	 detected	 in	 severe	 cases.	 	 The	 predominant	diagnostic	features	of	cOB	are	poorly	reversible	airflow	obstruction,	a	mosaic	pattern	of	decreased	attenuation	on	HRCT,	and	air	trapping	on	pulmonary	 function	 testing	 and/or	 expiratory	 HRCT	 images	 (Figure	 1).	 Chest	 radiographs	 are	 often	 normal,	 or	 may	 demonstrate	 only	hyperinflation,	until	cOB	is	advanced.	It	has	been	mainly	described	in	lung	and	stem	cell	transplant	patients	with	chronic	rejection	and	graft-versus-host	 disease,	 and	 as	 a	 sequela	 of	 community-acquired	 respiratory	 viral	 infections	 (i.e.,	 influenza,	 parainfluenza,	 adenovirus,	respiratory	 syncytial	 virus)	 and	 cytomegalovirus	 infection.	 It	 is	 very	 rarely	 reported	 among	 HIV-uninfected	 children	 after	 community-acquired	respiratory	viral	infections.		The	high	incidence	of	viral	infections	among	children	and	adolescents	with	HIV	may	play	an	important	
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role	in	development	of	cOB,	particularly	in	those	with	delayed	diagnosis	and	treatment	of	HIV	[25*].	Additionally,	decreased	attenuation	was	strongly	correlated	with	bronchiectasis	and	bronchial	wall	thickening	and	dilatation	on	HRCT	[8*],	suggesting	a	continuum	of	pathological	processes	that	links	small	and	large	airways	involvement.	Although	disease	course	and	prognosis	of	cOB	are	not	known	among	HIV-infected	adolescents,	in	other	populations,	cOB	responds	poorly	to	therapy	and	is	associated	with	a	high	risk	of	mortality	over	months	to	years.		
	
Lymphocytic	interstitial	pneumonitis	Globally,	LIP	was	the	most	common	cause	of	CLD	among	HIV-infected	children	during	the	pre-ART	era	[20,30,31].	It	is	generally	responsive	to	ART,	 although	 severe	LIP	may	 require	 adjunct	 corticosteroid	 therapy.	The	overall	 incidence	of	 LIP	has	declined	dramatically	with	 the	scale-up	of	ART,	 and	 in	 recent	 studies,	 LIP	 appears	 to	 be	 uncommon	among	older	 children	 and	 adolescents	with	HIV.	A	 review	of	 chest	radiographic	findings	in	HIV-infected	children	and	adolescents	reported	that	pulmonary	tuberculosis	and	LIP	accounted	for	70%	and	15%	of	cases,	respectively	[32*].	However,	 three-quarters	of	 included	studies	were	conducted	during	the	pre-	and	early	ART	era	or	 in	ART-naïve	individuals.	In	two	recent	studies	of	generally	ART-experienced	HIV-infected	adolescents	from	Zimbabwe,	HRCT	was	strongly	suggestive	of	LIP	in	<3%	[8*,16*].		
Asthma	Conflicting	 data	 suggest	 that	 asthma	 risk	 may	 be	 higher	 among	 HIV-infected	 compared	 with	 HIV-uninfected	 children	 and	 adolescents,	especially	in	high-income	settings	[33,34].	Among	1201	HIV-infected	adolescents	living	in	the	USA,	of	whom	87%	were	perinatally-infected	and	85%	were	taking	ART,	asthma	was	a	common	comorbid	condition	with	an	incidence	of	1.2/100	person-years	[35**].	In	a	study	of	Thai	children	 with	 perinatally-acquired	 HIV,	 early	 initiation	 of	 ART	 was	 associated	 with	 higher	 CD4,	 and	 the	 prevalence	 of	 asthma	 (27%)	exceeded	 that	 of	 uninfected	 Thai	 children	 (18%)	 [36*].	 Asthma	 tended	 to	 be	more	 common	 among	 individuals	with	 preserved	 immune	function,	and	may	be	linked	to	immune	reconstitution	[36*,37-39].	However,	the	prevalence	may	have	been	overestimated	in	these	studies,	as	diagnosis	was	based	on	self-report,	diagnostic	codes	or	prescription	of	asthma-related	medications.	In	a	study	that	performed	spirometry	in	216	perinatally	HIV-infected	adolescents	in	the	USA,	only	30%	of	those	with	airflow	obstruction	had	bronchodilator	reversibility	(overall,	9%	 of	 those	 with	 interpretable	 spirometry)	 [19*].	 In	 Zimbabwe,	 3-5%	 of	 older	 children	 and	 adolescents	 with	 perinatally-acquired	 HIV	reported	a	history	of	asthma	[13*,15*],	similar	to	the	prevalence	estimated	in	the	general	African	paediatric	population	[40].	Reversibility	
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with	bronchodilators	was	uncommon	in	African	studies	reporting	airflow	obstruction	among	HIV-infected	adolescents,	with	the	exception	of	one	South	African	study	in	which	15%	had	reversibility	[10*,11*,12*,13*,18**].	While	asthma	prevalence	may	be	underestimated	in	LMICs	where	 few	 systematic	 surveys	 have	 been	 completed,	 it	 is	 plausible	 that	 incidence	 is	 low,	 but	 could	 increase	 with	 industrialization,	 as	observed	in	South	Africa.		
	
Pulmonary	hypertension	HIV-related	pulmonary	arterial	hypertension	is	rare	with	an	estimated	prevalence	of	0.5%	among	adults	in	high-income	countries;	however,	small	studies	from	sub-Saharan	Africa	suggest	a	prevalence	of	5-13%	[41,42*].	Pulmonary	hypertension	is	rarely	described	in	HIV-infected	children	 and	 adolescents	 [43].	 A	 study	 in	 Zimbabwe	 reported	 that	 4%	 of	 perinatally	 HIV-infected	 adolescents	 had	 elevated	 estimated	pulmonary	 artery	 systolic	 pressure	 (>30	mmHg)	 on	 echocardiography	 [44].	 Overall,	 30%	 had	 right	 ventricular	 dilatation,	 and	 24%	 had	concurrent	 impaired	 left	 ventricular	 function.	 In	 another	 study,	 28%	 of	 HIV-infected	 children	 and	 adolescents	 had	 right	 ventricular	dilatation,	and	two-thirds	had	concomitant	left	heart	abnormalities	[45*].	Pulmonary	hypertension	prevalence,	however,	remains	uncertain	as	 echocardiography	 may	 over-	 or	 underestimate	 prevalence	 [46],	 and	 use	 of	 pulmonary	 angiography,	 the	 diagnostic	 gold	 standard,	 is	limited	in	LMICs.	HIV-related	pulmonary	hypertension	in	adolescents	may	be	multifactorial	as	a	sequela	of	HIV	itself	or	secondary	to	HIV-associated	immune	dysfunction	and/or	cardiopulmonary	disease	[42,47].		
Risk	factors	for	HIV-associated	chronic	lung	disease	among	adolescents	The	burden	of	CLD	among	HIV-infected	adolescents	appears	to	be	greater	in	LMICs.	This	may	be	due	to	a	higher	prevalence	of	risk	factors,	including	 pulmonary	 infections,	 household	 air	 pollution,	malnutrition	 and	 stunting	 [1,7**,48].	 Additionally,	 in	 contrast	with	 high-income	settings	where	the	majority	of	HIV-infected	children	initiate	ART	in	infancy,	a	substantial	proportion	of	children	are	diagnosed	with	HIV	and	initiate	ART	in	later	childhood.	Among	adolescents	with	delayed	diagnosis	of	perinatally-acquired	HIV	in	sub-Saharan	Africa,	older	age	and	low	FEV1	and	FVC	z-scores	appear	to	be	associated	[9*,11*,13*,15*].	This	might	reflect	accumulation	of	insults	over	time	and	survivor	bias.	Multiple	risk	factors	may	interact	to	predispose	to	CLD	(Figure	2).		
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Pulmonary	infections	Pulmonary	 pathogens	 can	 trigger	 local	 inflammation,	 resulting	 in	 scarring	 and	 destruction	 of	 lung	 tissue	 [49].	 Pulmonary	 infections,	including	 Pneumocystis	 jirovecii	 pneumonia	 (PCP),	 bacterial	 pneumonia,	 and	 tuberculosis	 are	 associated	 with	 permanent	 lung	 function	abnormalities	among	HIV-infected	adults	[50,51].	Recurrent	and	severe	pulmonary	infections	early	in	life	are	also	associated	with	impaired	lung	 function,	 and	 these	 early	 impairments	may	 track	 through	 later	 life	 [52*,53].	 Increasing	 availability	 of	ART	and	 co-trimoxazole	have	resulted	 in	 a	 decline	 in	 the	 incidence	 of	 bacterial	 pneumonia,	 pulmonary	 tuberculosis,	 and	 PCP	 [54,55].	 In	 LMICs,	 pulmonary	 infections	remain	common	despite	decreases	in	incidence,	and	risk	of	pulmonary	infections	is	particularly	high	among	those	with	delayed	diagnosis	and	treatment	of	HIV	[26,56*].		
HIV	infection,	systemic	immune	activation	and	chronic	inflammation	HIV	infection	is	associated	with	systemic	immune	activation	and	chronic	inflammation	[57-59].	This	is	driven	by	translocation	of	microbial	products,	including	lipopolysaccharide,	into	the	systemic	circulation	through	a	gastrointestinal	mucosa	made	“leaky”	as	a	result	of	HIV	HIV-mediated	inflammation	of	gut	 lymphoid	tissue	[59-61].	The	resultant	 immune	dysregulation	is	associated	with	end-organ	damage	[58,62-64],	and	may	be	important	mechanistically	in	CLD	development.	HIV	itself	 is	an	independent	risk	factor	for	COPD	among	adults	[6,65,66].	Preliminary	data	suggest	that	HIV	is	also	independently	associated	with	CLD	in	children	and	adolescents	[12*,15*,18**].	Infancy	and	early	childhood	are	critical	periods	for	organ	and	immune	system	development.	HIV-mediated	immune	dysregulation	may	place	children	at	high	risk	of	lung	damage,	particularly	those	with	untreated	HIV,	and	recurrent	pulmonary	infections	may	further	accelerate	lung	function	decline.	These	 pathophysiological	 mechanisms	may	 partly	 explain	 why	 adolescents	 in	 LMICs,	 where	 HIV	 diagnosis	 and	 ART	 initiation	 are	 often	delayed	[67*,68],	have	a	higher	prevalence	of	CLD.		While	ART	reduces	markers	of	inflammation,	residual	systemic	immune	activation	and	chronic	inflammation	persist	[61,69].	The	impact	of	ART	 on	 the	 course	 of	 CLD	 remains	 unclear.	 An	African	 study	 reported	 a	 lower	 prevalence	 of	 cough,	 breathlessness	 and	 hypoxia,	 but	 no	difference	in	lung	function	among	HIV-infected	adolescents	who	had	received	ART	for	a	median	of	five	years	compared	to	an	age-matched	
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group	of	ART-naïve	adolescents	 [14*].	Among	HIV-infected	Kenyan	adolescents	and	adults,	perinatally-acquired	HIV	and	nadir	CD4	<200	cells/µL	 were	 associated	 with	 airflow	 obstruction	 despite	 near	 universal	 ART	 use	 [12*].	 Additionally,	 in	 Zimbabwe	 and	 South	 Africa,	adolescents	 with	 HIV	 had	 significantly	 decreased	 FEV1	 and	 FVC	 z-scores,	 lung	 volumes,	 and	 compliance	 compared	 to	 uninfected	 peers,	despite	a	greater	than	six-year	median	duration	of	ART	use	[15*,18**].		
	
Tobacco	smoke	and	air	pollution		Exposure	to	tobacco	smoke,	both	prenatally	and	during	infancy,	is	associated	with	impaired	lung	function	in	one	year	olds	[52*].	Cigarette	smoking	 is	 a	 recognized	 risk	 factor	 for	 chronic	obstructive	pulmonary	disease	 (COPD)	and	 lung	 function	decline	among	adults.	 Levels	of	cigarette	smoking	are	increasing	among	adolescents,	particularly	in	LMICs	[70].	Therefore,	tobacco	smoke	exposure	will	 likely	become	an	increasingly	important	contributor	to	development	of	CLD.		Exposure	to	household	air	pollution	during	early	life	has	been	associated	with	mortality	and	pulmonary	infections,	which	in	turn	may	impair	lung	function	[48,71*,72].	Strong	evidence	also	supports	the	association	between	household	air	pollution	and	CLD,	including	COPD	in	adults	and	wheezing	in	children	[48].	To	date,	no	studies	have	demonstrated	a	link	between	household	air	pollution	and	CLD	among	HIV-infected	adolescents,	likely	due	to	confounding	by	other	exposures	and	difficulties	in	measuring	exposures.		
Malnutrition	and	stunted	growth	Both	malnutrition	and	stunting	are	common	among	children	and	adolescents	living	with	HIV	in	LMICs,	with	prevalence	estimated	as	high	as	42%	and	73%,	respectively	[10*,73-76].	Malnutrition	during	the	first	year	of	life	is	associated	with	decreased	lung	function	at	one	year	of	age	[52*].	In	a	Kenyan	study,	stunting	was	associated	with	tachypnoea	among	HIV-infected	adolescents	[9*].	Stunting	is	a	marker	of	delayed	somatic	growth;	therefore,	stunted	children	are	likely	to	have	smaller	lungs	[77*],	which	may	subsequently	predispose	to	CLD.		
Assessment	and	management	of	chronic	lung	disease		
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Awareness	of	the	burden	and	spectrum	of	HIV-associated	CLD	is	limited.	Several	studies	have	proposed	criteria	for	defining	CLD	in	children	and	adolescents	[8*,11*,56*],	but	a	sensitive	and	specific	clinical	algorithm	has	not	been	established.	Chest	radiographic	abnormalities	are	nonspecific	for	many	CLD	subtypes	and	may	be	visible	only	in	late	stages	of	disease.	Availability	of	diagnostic	modalities	such	as	spirometry	and	HRCT	is	limited	in	LMICs.			In	 the	 absence	 of	 appropriate	 diagnostics,	 chronic	 respiratory	 symptoms	 are	 frequently	 empirically	 treated	 with	 repeated	 courses	 of	antibiotics	 and	anti-tuberculosis	 therapy	 in	high	HIV	prevalence	 settings	where	 tuberculosis	 is	 common	 [8*,15*,17].	The	pathogenesis	of	CLD	 is	 poorly	 understood,	 and	 there	 are	 no	 specific	management	 guidelines.	 However,	 prevention	 of	 pulmonary	 infections	 by	 ensuring	routine	vaccinations,	early	ART	initiation	and	continued	co-trimoxazole	use	may	mitigate	the	burden	of	CLD	among	HIV-infected	adolescents	[78].			
Future	directions	Prospective	 studies	 to	 understand	 the	 natural	 history,	 pathology	 and	 pathogenesis	 of	 CLD	 in	 HIV-infected	 adolescents	 are	 needed.	Standardization	of	the	definition	of	CLD	and	of	data	collection/measurement	will	allow	for	comparability	across	studies	and	merging	of	data	to	achieve	greater	power	to	detect	associations.	Additionally,	locally-derived	references	for	defining	abnormal	lung	function	in	children	are	needed	in	LMICs.	The	2016	WHO	HIV	guidelines	recommend	treatment	of	all	individuals	regardless	of	age	or	immune	status,	which	should	facilitate	earlier	ART	initiation.	However,	once	established,	CLD	does	not	appear	to	be	completely	reversed	by	ART.	Screening	algorithms	for	CLD	 for	 children	and	adolescents	need	 to	be	developed,	 and	 interventions	 such	as	 long-term	macrolide	 therapy,	prophylactic	antibiotics,	pulmonary	rehabilitation	and	tobacco	smoke	avoidance/cessation	programmes	require	evaluation.	
	
Conclusion	Recent	studies	demonstrate	a	high	burden	of	CLD	and	its	manifestations	among	HIV-infected	older	children	and	adolescents,	particularly	in	LMICs.	 CLD	 represents	 a	 spectrum	 of	 conditions	with	 overlapping	 risk	 factors	 and	 pathogenic	mechanisms.	 As	 greater	 numbers	 of	HIV-
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infected	children	survive	to	adolescence,	the	prevalence	of	CLD	in	this	age-group	is	likely	to	increase.	Further	research	is	urgently	needed	to	develop	optimal	diagnostic	and	therapeutic	strategies	so	as	to	avoid	compromising	the	substantial	gains	in	mortality	accomplished	with	ART	among	HIV-infected	children.  
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Key	points		1.	Chronic	lung	disease	is	increasingly	recognized	as	a	complication	among	older	children	and	adolescents	with	perinatally-acquired	HIV.		2.	The	burden	of	chronic	lung	disease	disproportionally	affects	those	living	in	LMICs.	3.	 The	most	 common	 causes	 of	 chronic	 lung	 disease	 appear	 to	 be	 large	 and	 small	 airways	 disease,	 which	may	 be	 poorly	 responsive	 to	antiretroviral	therapy	once	established		4.	The	prevalence	and	incidence	of	lymphocytic	interstitial	pneumoniitis	appear	to	have	decreased	dramatically	with	the	global	scale-up	of	antiretroviral	therapy.		
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Study,	
year	
Location,	
participant	N	
Characteristics	of	HIV-infected	
adolescents	 Respiratory	symptoms/signs	 Abnormal	spirometry	Ferrand,		et	al.	[8*],	2012	 Harare,	Zimbabwe	N=116	 • Mean	age:	14	±	2.6	years	• 43%	male	• Mean	age	at	HIV	diagnosis:		12	years	
• Perinatally-acquired	HIV:	100%	
• 69%	on	ART	for	median	duration	of	2	years		
• 66%	chronic	cough	
• 21%	reduced	exercise	tolerance	
• 10%	digital	clubbing	
• 13%	SaO2	<92%	at	rest	
• 29%	hypoxia	after	sub-maximal	exercise	
• 28%	respiratory	rate	>25	bpm	
• OBSTRUCTED:	52/116	(45%)	based	on	FEV1	<80%	predicted		 – Predicted	values	based	on	age-,	sex-,	and	height-adjusted	standards	in	healthy	Malawian	schoolchildren	
McHugh,		et	al.	[10*],	2016	 Harare,	Zimbabwe	N=385	 • Median	age:	11	[6-15]	years	• 48%	male	• Median	age	at	HIV	diagnosis:	11	years	
• Perinatally-acquired	HIV:	95%	
• All	ART-naïve	
• 54%	cough	>1	month	
• 16%	MRC	dyspnoea	score	≥2	
• 14%	SaO2	<88%	
• 10%	with	SaO2	<88%	after	sub-maximal	exercise	
• OBSTRUCTED:	23/238	(10%)	had	FEV1	and	FEV1/FVC	<1.64	SD	below	mean		– 3	had	bronchodilator	reversibility		
• RESTRICTED:	43/238	(18%)	had	FVC	<1.64	SD	below	mean	and	normal	FEV1/FVC	Mwalukomo,	et	al.	[11*],	2016	 Blantyre,	Malawi	N=160	 • Median	age:	11	[10-12]	years	• 50%	male	• Median	age	at	HIV	diagnosis:		8	years	
• Perinatally-acquired	HIV:	56%	
• 74%	on	ART	for	median	duration	of	4	years	
• 38%	cough	
• 34%	moderate/severe	dyspnoea	
• 22%	digital	clubbing	
• 21%	SaO2	<92%	
• 36%	respiratory	rate	>24	bpm	
• OBSTRUCTED:	26/145	(18%)	had	FEV1	and	FEV1/	FVC	<LLN	using	GLI	2012	equations	
• RESTRICTED:	29/145	(20%)	had	FVC	<LLN	and	FEV1/FVC	≥LLN	using	GLI	2012	equations	
• 15	of	55	with	abnormal	spirometry	had	bronchodilator	reversibility,	but	overall	median	increase	in	FEV1	only	3%	Attia,	et	al.		[12*],	2015	 Nairobi,	Kenya	N=55	 • Median	age:	13	[11-14]	years	• 54%	male	• Age	at	HIV	diagnosis:		Not	reported	
• Perinatally-acquired	HIV:	100%	
• 95%	on	ART		
• 60%	cough	
• 51%	sputum	production	
• 31%	wheeze	(self-reported)	
• 11%	SaO2	≤92%	
• 38%	SaO2	≤92%	after	sub-maximal	exercise	
• OBSTRUCTED:			– 10/55	(18%)	pre-bronchodilator	FEV1/	FVC	<0.7		– 8/55	(15%)	post-bronchodilator	FEV1/FVC	<0.7			
Rylance	S,		et	al.	[14*],	2016	 Harare,	Zimbabwe	N=385	ART-naïve	and	202	ART-treated	
• Median	age:	11	[9-13]	years	
• 45%	male	
• Median	age	at	HIV	diagnosis:		11	years	among	ART-naïve	vs	6	years	among	ART-treated	
• Perinatally-acquired	HIV:	100%	
• Median	duration	of	ART	use:	6	years	among	ART-treated	
ART-naïve	compared	to	ART-treated:	
• Daily	cough	in	53	vs	15%	
• Dyspnoea	in	12	vs	15%	
• Resting	hypoxia	in	14	vs	1%	
• Greater	exercise	limitation	(walked	460	vs	770	m	on	shuttle	walk	testing)	
ART-naïve	compared	to	ART-treated:	
• Abnormal	spirometry	in	26	vs	24%	
• OBSTRUCTED:	24/262	(9%)	vs	7/177	(4%)	
• RESTRICTED:	43/262	(16%)	vs	36/177	(20%)	– based	on	reduced	FVC	
Rylance	J,		et	al.	[15*],	2016	 Harare,	Zimbabwe	N=202	HIV- • Median	age:	11	[9-13]	years	• 51%	male	• Median	age	at	HIV	diagnosis:		 HIV-infected	compared	to	HIV-uninfected:	• Daily	cough	in	15	vs	1%	 HIV-infected	compared	to	HIV-uninfected:		• OBSTRUCTED:	4/177	(4%)	vs	1/130	(1%)	• RESTRICTED:	36/177	(20%)	vs	14/130	(11%)	
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infected	and	150	age-matched	HIV-uninfected	
6	years	
• Perinatally-acquired	HIV:	99.5%	
• All	HIV-infected	receiving	ART;	ART	initiated	at	a	median	age	of	6	years	
• Dyspnoea	in	15	vs	0%	
• Sputum	production	in	10	vs	1%	
• Respiratory	rate	>25	bpm	in	14	vs	6%	
• Greater	exercise	limitation	(walked	771	vs	889	m	on	shuttle	walk	testing)	
– based	on	reduced	FVC	
• 11/31	(36%)	vs	2/6	(33%)	had	bronchodilator	reversibility	(only	those	with	abnormal	spirometry	were	tested)			Githinji,	et	al.	[18**],	2016	 Cape	Town,		South	Africa	N=515	HIV-infected	and	110	age-,	sex-,	ethnically-matched	HIV-uninfected	controls	
• Mean	age:	12	±	1.6	years	
• 52%	male	
• Age	at	HIV	diagnosis:		Not	reported	
• Perinatally-acquired	HIV:	100%	
• Median	duration	of	ART	use:	8	years	
Not	reported	 HIV-infected	compared	to	HIV-uninfected:		
• OBSTRUCTED:	44/515	(9%)	among	HIV-infected	– FEV1:	1.60	L	in	HIV-infected	vs	1.86	L	in		HIV-uninfected	
• RESTRICTED:	75/515	(15%)	among	HIV-infected	based	on	measured	lung	volumes	– FVC:	1.80	L	in	HIV-infected	vs	2.00	L	in		HIV-uninfected	
• 75/515	(15%)	vs	9/110	(8%)	had	bronchodilator	reversibility		
à	Overall,	HIV-infected	had	reduced	lung	function	(i.e.,	lung	volumes,	airflow,	compliance)	compared	to	HIV-uninfected	Shearer,		et	al.	[19*],	2015	 United	States	(multiple	sites)	N=216	HIV-infected	and	151	HIV-exposed	uninfected	
• Median	age:	17	[14-19]	years		
• 42%	male	
• Age	at	HIV	diagnosis:		Not	reported	
• Perinatally-acquired	HIV:	100%	
• ART	use:	Not	reported		
Not	reported	 HIV-infected	compared	to	HIV-uninfected:		
• OBSTRUCTED:	42/188	(22%)	vs	28/132	(21%)	had	FEV1	<80%	or	FEV1/FVC	<0.8	
• RESTRICTED:	18/188	(10%)	vs	17/132	(13%)	had	FVC	<80%	and	FEV1/FVC	≥0.8	
• 17/188	(9%)	vs	21/132	(17%)	had	bronchodilator	reversibility		–	Predicted	values	calculated	based	on	normative	equations	generated	using	values	from	healthy	children	in	NHANES	III									
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		A,	Image	section	at	the	level	of	the	carina	in	a	15-year-old	female.	There	is	a	clear	zone	of	decreased	attenuation	in	the	right	upper	lobe	(and,	to	a	lesser	extent,	the	left	lung).	In	regions	of	decreased	attenuation	there	is	reduction	in	the	caliber	of	pulmonary	vessels;	there	was	no	bronchiectasis	in	this	patient.	B,	Image	section	in	a	19-year-old	male	through	the	lower	zones	demonstrating	focal	areas	of	decreased	attenuation	in	both	lungs	(arrows)	and	bronchiectasis	in	the	left	lower	lobe	(arrowheads).			
23		
Figure	1:	Aetio-pathogenesis	of	chronic	lung	disease	in	HIV-infected	adolescents	(+	Increases	risk;	-	decreases	risk)		
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